ReviewEuropean journal of haematology2026
Light Chain Monoclonal Gammopathy of Undetermined Significance: Diagnosis, Biology, and Clinical Management.
Review in European journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Light chain monoclonal gammopathy of undetermined significance (LC-MGUS) is defined by an abnormal serum free light chain ratio and elevated involved light chain in the absence of a detectable immunoglobulin heavy chain on immunofixation and of end-organ damage attributable to a plasma cell disorder. It is the least characterized of the MGUS subtypes and the one whose accurate diagnosis is most dependent on the precision of the reference intervals used to interpret free light chain measurements. Population-based screening has demonstrated that standard reference intervals substantially overdiagnose LC-MGUS through three independent mechanisms: age-related physiological free light chain elevation, impaired renal clearance in chronic kidney disease, and ancestry-related differences in individuals of African descent. Revised age-stratified and kidney function-adjusted reference intervals reduce LC-MGUS prevalence by 82%, with no observed progressions among reclassified individuals during available follow-up of 4.6 years and have been validated across multiple independent international cohorts. For individuals of African ancestry, ancestry-adjusted reference intervals provide a further essential and independent correction. True LC-MGUS progresses along two biologically distinct trajectories: clonal expansion toward light chain multiple myeloma and toxic light chain misfolding toward AL amyloidosis. These pathways differ fundamentally in biology, determinants of progression, and clinical consequences. Risk models designed to predict myeloma progression incompletely capture the risk of amyloidogenic transformation. Because amyloidogenic transformation can occur in the setting of low clonal burden and only modestly abnormal free light chain levels, clinical evaluation must independently and explicitly address both trajectories at every patient encounter.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.